“Four-Weekly Dosing Intervals With Subcutaneous Spesolimab Appear to Be Required for Optimal Prevention of Generalized Pustular Psoriasis Flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON Trials”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s492. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/3138.